Skip to main content
SpringerLink
Log in

shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Design short hairpin RNA (shRNA) interference sequence to silence glutathione S-transferase P1 (GSTP1) gene of androgen-independent prostate cancer cell line DU145, and then to explore its effect on sensitivity to chemotherapeutics.

Methods

Target sequence was picked up to form the shRNA. DU145 cell was divided into five groups according to the shRNA added for transfection: shRNA255, shRNA554, shRNA593, negative-shRNA and blank group. Fluorescence microscope was used to pick up the shRNA with the highest transfection ratio. Western blotting and RT-PCR were taken to pick up the shRNA with the best gene silencing result. 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay and terminal de-oxynucleotidyl transferase-mediated dUTP nick end-labeling assay were used to detect survival ratio and apoptosis ratio of DU145 administered of fluorouracil (5-FU) or paclitaxel (PA) at different concentrations before and after shRNA transfection.

Results

Three different shRNA oligonucleotides (shRNA255; shRNA554; shRNA593) targeting the coding sequence of GSTP1 mRNA and one negative control shRNA were constructed. The transfection ratio of shRNA554 (76.2 ± 0.68 %) was higher than that of shRNA255 (63.3 ± 1.04 %) (P < 0.01) or shRNA593 (72.7 ± 0.33 %) (P < 0.01). After transfection of shRNA554, the mRNA and protein of level were the lowest, P < 0.01. The survival ratio of DU145 administered with 5-FU of different concentrations (30, 60, 120, 240 μg/ml) declined after transfection (P < 0.01). Besides, the apoptosis ratio increased after transfection (P < 0.01). Similarly the survival ratio of DU145 administered with PA of different concentrations (0.2, 2, 10, 20 μg/ml) declined (P < 0.01) and the apoptosis ratio increased (P < 0.01) after transfection.

Conclusions

The gene GSTP1 silence via shRNA transfection to androgen-independent prostate cancer cell line DU145 enhances the sensitivity to chemotherapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3):481–488

    Article  CAS  PubMed  Google Scholar 

  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403

    Article  CAS  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA: Cancer J Clin 58(2):71–96

    Google Scholar 

  4. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45

    Article  CAS  PubMed  Google Scholar 

  5. Heidenreich A, von Knobloch R, Hofmann R (2001) Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 39(2):121–130

    Article  CAS  PubMed  Google Scholar 

  6. Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T (2008) Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis 29(6):1134–1138

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ (2011) Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16(1):74–82

    Article  CAS  PubMed  Google Scholar 

  8. Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K (2012) Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology 59(113):130–133

    Article  CAS  PubMed  Google Scholar 

  9. Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE (2003) Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate 56(2):98–105

    Article  CAS  PubMed  Google Scholar 

  10. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806–811

    Article  CAS  PubMed  Google Scholar 

  11. Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14(9):893–900

    Article  CAS  PubMed  Google Scholar 

  12. Yang Y, Zhou Z, He S, Fan T, Jin Y, Zhu X, Chen C, Zhang ZR, Huang Y (2012) Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-fluorouracil conjugates. Biomaterials 33(7):2260–2271

    Article  CAS  PubMed  Google Scholar 

  13. Iida K, Zheng R, Shen R, Nanus DM (2012) Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer. Int J Oncol 41(4):1192–1198

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Bostwick DG, Meiers I, Shanks JH (2007) Glutathione S-transferase: differential expression of alpha, mu, and pi isoenzymes in benign prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Hum Pathol 38(9):1394–1401

    Article  CAS  PubMed  Google Scholar 

  15. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E (2005) Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. The Prostate 63(3):240–251

    Article  CAS  PubMed  Google Scholar 

  16. O’Brien ML, Vulevic B, Freer S, Boyd J, Shen H, Tew KD (1999) Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 291(3):1348–1355

    PubMed  Google Scholar 

  17. Eilers T, Machtens S, Tezval H, Blaue C, Lichtinghagen R, Hagemann J, Jonas U, Serth J (2007) Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate. Prostate 67(7):757–763

    Article  CAS  PubMed  Google Scholar 

  18. Lu M, Xia L, Luo D, Waxman S, Jing Y (2004) Dual effects of glutathione-S-transferase-P1 on As203 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 23(22):3945–3952

    Article  CAS  PubMed  Google Scholar 

  19. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME (2008) Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 102(3):389–397

    Article  CAS  PubMed  Google Scholar 

  20. Naiki T, Asamoto M, Toyoda-Hokaiwado N, Naiki-Ito A, Tozawa K, Kohri K, Takahashi S, Shirai T (2012) Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice. Prostate 72(5):533–541

    Article  CAS  PubMed  Google Scholar 

  21. Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173(1):10–20

    Article  PubMed  Google Scholar 

  22. Saleh EM, El-Awady RA, Anis N (2013) Predictive markers for the response to 5-fluorouracil therapy in cancer cells: constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy. Oncol Lett 5(1):321–327

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors report no conflicts of interest in this work.

Author information

Authors and Affiliations

  1. Centre of Organ Transplantation, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu Area, Changsha, 410008, China

    Peng Jin, Jinliang Xie, Xiangrong Zhu, Cheng Zhou & Xiang Ding

  2. Department of Urology, Second Xiangya Hospital, Central South University, Changsha, 410011, China

    Luoyan Yang

Authors
  1. Peng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinliang Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiangrong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cheng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiang Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luoyan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peng Jin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jin, P., Xie, J., Zhu, X. et al. shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity. Int Urol Nephrol 46, 1115–1121 (2014). https://doi.org/10.1007/s11255-013-0616-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-013-0616-7

Keywords

Search

Navigation